Protocol Ledger

NCT06050122 · Phase III · COMPLETED

Efficacy and Safety of Patidegib Gel 2% for Preventing Basal Cell Carcinomas on the Face of Adults With Gorlin Syndrome

Interventional Phase III clinical trial protocol NCT06050122 sponsored by Sol-Gel Technologies in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-03-17 Enrollment: 113 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT06050122
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)113 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06050122
Protocol FieldVerified Registry Value
NCT IdentifierNCT06050122
Consolidated Lead SponsorSol-Gel Technologies
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment113 participants (ACTUAL)
Registered Start Date2024-03-17
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI